The Journal for ImmunoTherapy of Cancer (JITC) welcomes submissions in the following areas and related topics:
Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the antitumor immune response, and oncolytic viruses.
Reports on unusual or unexpected clinical cases that expand the field of general medical knowledge. Includes information on an unexpected association between diseases or symptoms, an unexpected event in the course of observing or treating a patient, findings that shed new light on the possible pathogenesis of the disease or an adverse effect, unique or rare features of the disease, and/or a unique therapeutic approach.
First-in-man clinical trials, phase II/III clinical studies, immune monitoring investigations, tumor microenvironment, host genetics and clinical outcome, combination therapies, and cell therapies.
Announcements and updates of cancer immunotherapy clinical trials in progress. Includes perspectives and implications of late stage pivotal clinical trials results and new regulatory approvals. Articles may also focus on other pertinent regulatory issues to help define a road map for navigating the clinical trial landscape.
Reaction to and/or perspectives on significant events in the field in the basic science area. May address a critical challenge, elaborate or extend a conversation of a focal article, provide an application of a theoretical perspective, or shed light on a particular issue in the field.
Predictive/prognostic biomarker studies, gene expression studies in cancer immunotherapy, serological immune biomarkers, multiparameter flow cytometry-defined immune biomarkers, high content immunohistological studies, clinical trial analyses and identification of novel immune biomarkers.
Fact/data-driven works that cumulate several articles of importance on a particular subject or research area in a review format with the goal of providing the state-of-the-art in the field. Includes recent major advances and discoveries, significant gaps in the research, current debates, and/or ideas of where research might go next.
Content freely available upon publication.
Articles published within 2-4 weeks of acceptance.
JITC touts an impact factor of 8.374, which it first received in June 2018. JITC’s impact factor ranks in the top 8 percent of all journals published in the categories of oncology and immunology.
Featured in six major indexing resources including:
Published by BioMed Central, a member of the Committee on Publishing Ethics.
Monthly JITC Digest sent to global experts and Twitter coverage.
Recipients Receive $1,000* and recognition at SITC's Annual Meeting.
*Papers published between August 2016 to September 2017 authored by SITC members are eligible for nomination for awards. Papers on which the first or senior author is a SITC member are eligible for consideration. Join SITC, renew your membership, or check your current membership status.
Submit your Manuscript to JITC
Cancer rates across the Middle East are expected to double between 2012 and 2030, according to World Health Organization (WHO) estimates-the highest relative increase of any region globally. This rise is caused by a combination of environmental ...
The cited editorial states that even with modest survival benefits, tripling of PFS as related to the PACIFIC trial of use of durvalumab immediately after chemoradiotherapy is commendable. Given minimal side effects, its addition should be considered ...
Dear Colleagues ,
Sidra Medicine is proud to host Qatar's first International Workshop on Engineered Immune Cells in Cancer Immunotherapy (EICCI): from Discovery to "Off-the shelf" Development.
Translating the potency of the anti-cancer immune ...
Dear Colleagues ,
It is our distinct pleasure to invite you to attend the Global Conference on Cancer & Oncology Research taking place at Dubai, UAE.
Date: Monday 04 and Tuesday 05 March 2019
Venue: Radisson Blu Hotel, Dubai Waterfront ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org